Clinical trials: sponsored by Celgene
Newly Diagnosed Multiple Myeloma
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
- Trial name
- NCT00405756
- Testing
- Lenalidomide: Double-blind Induction, Melphalan, Prednisone
- Where
- 98 sites in Australia, Austria and 20 more
- Volunteers
- 459 people
- Sponsor
- Celgene Corporation
Breast Neoplasms, Metastases, Neoplasm
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against metastatic breast cancer. However, the Taxol formulation requires prolonged administration times, and there are safety problems that have…
- Trial name
- NCT00046514
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Celgene Corporation
Non-Small Cell Lung Cancer
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
The anticancer agent paclitaxel (Taxol for Injection Concentrate, Bristol-Meyers Squibb) has a broad spectrum of activity against several human cancers including carcinomas of ovary, breast, lung, esophagus and head and neck…
- Trial name
- NCT00073723
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Celgene Corporation
Colorectal Neoplasms, Diarrhea
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer.
- Trial name
- NCT00040391
- Testing
- Investigational drug, Irinotecan, 5-fluorouracil
- Where
- 28 sites in United States
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT00091624
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Celgene Corporation
Ovarian Cancer
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-14 when given with topotecan on days 1-5 of every 21 day cycle Phase II will commence once the MTD is established, additional subjects…
- Trial name
- NCT00179712
- Testing
- CC-5013, topotecan
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Crohn's Disease
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease
- Trial name
- NCT00446433
- Testing
- CC-5013
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 90 people
- Sponsor
- Celgene Corporation
Neoplasms, Metastases, Neoplasm
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies.
- Trial name
- NCT00046423
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT02011113
- Testing
- Pomalidomide, Dexamethasone
- Where
- 14 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Breast Neoplasms
Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. The study will be conducted by reviewing the medical records of patients up to the start of the study.
- Trial name
- AMBER (NCT02655159)
- Where
- 19 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Celgene Corporation
Pharmacokinetics
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel.
- Trial name
- NCT02820935
- Testing
- CC-220, Rifampin, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Multiple Myeloma
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory…
- Trial name
- NCT00833833
- Testing
- Pomalidomide, Dexamethasone, Aspirin
- Where
- 19 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Celgene Corporation
Leukemia Lymphocytic Chronic B-Cell
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD).
- Trial name
- NCT01744626
- Testing
- CC-292, Rituximab
- Where
- 8 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Non-Hodgkins Lymphoma
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
- Trial name
- NCT00179660
- Testing
- Lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
- Trial name
- NCT00057564
- Testing
- A (Thalidomide + Dexamethasone)
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 470 people
- Sponsor
- Celgene Corporation
Healthy Subjects
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
This is a two-part, phase 1 study to evaluate the pharmacokinetics and pharmacodynamics of multiple doses of CC-90001 and the effects of food and formulation on the pharmacokinetics of single dose CC-90001 in healthy subjects.
- Trial name
- NCT02321644
- Testing
- CC-90001
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
To identify the maximum tolerated dose (MTD) of oral azacitidine on different treatment schedules in Japanese subjects with hematological neoplasms
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01908387
- Testing
- Oral azacitidine
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Celgene Corporation
Healthy Volunteers
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001
First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of CC-90001
- Trial name
- NCT02110420
- Testing
- CC-90001
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Metastatic Melanoma
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in…
- Trial name
- NCT01933061
- Testing
- Abraxane
- Sponsor
- Celgene Corporation
Healthy Volunteers
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
- Trial name
- NCT02034773
- Testing
- CC-220
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation